Percutaneous electrification patch

Abstract

To provide a percutaneous electrification patch capable of enhancing an improving operation of a target portion of a subject.SOLUTION: A percutaneous electrification patch 1 comprises: an electrode 10 having an anode electrode 11 and a cathode electrode 12; and conductive parts 20A and 20B disposed so as to contact with the electrode 10. In the percutaneous electrification patch 1, the anode electrode 11 and the cathode electrode 12 are brought into contact with a target portion of a subject via the conductive parts 20A and 20B to form an electric circuit which causes a feeble current to flow through the portion. The feeble current caused to flow through a living body by the electric circuit is a direct current with a current density that is equal to or more than 0.5μA / cm2 and less than 500μA / cm2.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a transdermal electrical patch. [Background technology]

[0002] Patent Documents 1 to 3 disclose various examples of electro-patch devices that can provide electro-stimulation. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Laid-Open No. 2016-144634 [Patent Document 2] Japanese Patent Application Laid-Open No. 2016-067401 [Patent Document 3] Patent Publication No. 2021-115330 Summary of the Invention [Problem to be solved by the invention]

[0004] Patent Document 1 discloses an energizing patch that can pass an extremely small amount of current through a living body. Experiments have confirmed that this energizing patch can pass an extremely small amount of current, for example, 0.1 μA to 2 μA or 4 μA to 5 μA (see paragraphs 0029 and 0030 of Patent Document 1). Furthermore, according to a simulation test described below, the current density of the current passing through this energizing patch is, for example, 0.5 μA / cm. 2 Although Patent Document 1 proposes using such an electroconductive patch for treatment, the improvement effect when using the electroconductive patch for treatment has not been verified, and the improvement effect is unknown. However, there is a demand for using a small treatment device such as an electroconductive patch to improve a target area in the body (for example, to relieve pain), and it is desirable to provide such an electroconductive patch.

[0005] An object of the present invention is to provide a transdermal electropigmentary patch that can improve the improving effect on the target area. [Means for solving the problem]

[0006] (1) One aspect of the present invention relates to a transdermal electrophoresis patch. This transdermal electrophoresis patch includes a plurality of electrodes having positive and negative electrodes, and a conductive layer arranged to contact the plurality of electrodes. In this transdermal electrophoresis patch, an electric circuit is formed that passes a weak current through the living body by bringing the positive and negative electrodes into contact with the living body via the conductive layer. The weak current passed through this electric circuit is 0.5 μA / cm. 2 More than 500μA / cm 2 It is a direct current having a current density less than

[0007] In this transdermal electropatch, an electric circuit is formed that passes a weak current through the living body by contacting the positive and negative electrodes with the living body via a conductive layer, and the weak current that the electric circuit passes through the living body is 0.5 μA / cm 2 More than 500μA / cm 2 According to the findings of the present inventors, the weak current flowing through the living body is a very small current (for example, 0.2 μA / cm 2 ) which is higher than 0.5μA / cm 2 It has been found that by using a direct current of 500μA / cm or more, the effect of improving the target area can be significantly improved. Therefore, this transdermal electropatch can improve the effect of improving the target area. In addition, when the current density of the current applied to the body is 500μA / cm, 2 If the current density exceeds this, the user may feel irritation. Therefore, in this transdermal current patch, the current density applied to the body is set to 500 μA / cm 2 This allows the transdermal electropatch to be used for a long period of time (for example, by attaching it to a specific area on the user's body), further improving the effect on the target area.

[0008] (2) In the transdermal current patch described in (1) above, the electrical circuit has a current density of 10 μA / cm when connected to a resistance of 5 kΩ. 2 It is preferable that the DC current is set to a value equal to or greater than 1000 V. In this case, the effect of improving the target area can be more reliably improved.

[0009] (3) In the transdermal current patch of (1) or (2) above, the electrical circuit has a current density of 35 μA / cm when connected to a resistance of 5 kΩ. 2 It is preferable that the DC current is set to a value equal to or greater than 1000 V. In this case, the effect of improving the target area can be further improved.

[0010] (4) In any one of the above (1) to (3) transdermal energizing patches, the electric circuit has a current density of 60 μA / cm when connected to a resistance of 5 kΩ. 2 It is preferable that the DC current is set to a value equal to or greater than 1000 V. In this case, the effect of improving the target area can be further improved.

[0011] (5) In any of the above (1) to (4) transdermal current-carrying patches, when connected to a resistance of 1 kΩ, the current density is 500 μA / cm 2 In this case, the user will not feel any irritation regardless of the condition of their skin, allowing them to use the transdermal electro-patch for a longer period of time with more certainty, thereby further improving the effect of improving the target area.

[0012] (6) In any one of the above (1) to (5) transdermal current-carrying patches, the electric circuit is connected to a resistance of 5 kΩ and the current density of the weak current flowing therethrough is 10 μA / cm 2 at the latest after 10 minutes have elapsed. 2 More than 175μA / cm 2 The patch may be configured as follows: In this case, by attaching the transdermal electrolyzing patch to the target area for a long period of time, it is possible to continuously improve the improving effect on the target area.

[0013] (7) The transdermal electropatch according to any one of (1) to (6) above further includes a connector for electrically connecting the plurality of electrodes, the conductive layer being composed of a plurality of conductive portions corresponding to the positive and negative electrodes, each of the plurality of conductive portions having a sponge with bubbles and a buffer made of an electrolyte, with the solid buffer being exposed on the inner wall surfaces of the bubbles, and at least one of the plurality of electrodes preferably carrying an enzyme that catalyzes a redox reaction. In this case, the electrode carrying the enzyme preferably has an electron transfer mediator immobilized thereon, and more preferably the electron transfer mediator is a quinone compound or a phenylenediamine compound. This configuration more reliably ensures that the weak current applied to the living body falls within any of the aforementioned ranges, thereby more reliably improving the effect of improving the target area.

[0014] (8) In any of the above (1) to (7) transdermal current-carrying patches, the area of ​​each of the multiple electrodes is 80 cm 2 In this case, the transdermal energizing patch can be made smaller, making it easier to attach the transdermal energizing patch to the target area of ​​the user for a long period of time, thereby further improving the improvement effect on the target area.

[0015] (9) In another aspect, the present invention relates to a method for operating a transdermal energizing patch. In this method, a weak current is passed through a living body using any one of the above-described transdermal energizing patches (1) to (7). This operation can improve the improving effect on the target area. [Effects of the Invention]

[0016] According to the present invention, the improving effect on the target site can be improved. [Brief explanation of the drawings]

[0017] [Figure 1] FIG. 1 is an exploded perspective view of a transdermal energizing patch according to one embodiment of the present invention. [Figure 2]FIG. 2 is a schematic diagram showing the relationship between the catalyst and the electron transfer mediator in the anode electrode of the transdermal current patch shown in FIG. [Figure 3] FIG. 3 is a graph showing the current density flowing through the living body due to the transdermal energizing patch shown in FIG. [Figure 4] FIG. 4 is a graph showing an example of the current density of the transdermal energizing patch shown in FIG. [Figure 5] FIG. 5 is a graph showing the results of evaluating delayed muscle pain using a transdermal electrolyzing patch. [Figure 6] FIG. 6 is a graph showing the results of evaluating exercise performance using a transdermal electroconductive patch. [Figure 7] FIG. 7 is a graph showing the results of an evaluation of the relief of stiff shoulders using a transdermal energizing patch. [Figure 8] FIG. 8 is a graph showing an example of the results of evaluating the relief of temporomandibular joint disorders using a transdermal electroconductive patch. [Figure 9] FIG. 9 is a graph showing another example of the results of evaluating the relief of temporomandibular joint disorders using a transdermal electroconductive patch. [Figure 10] FIG. 10 is a diagram showing a schematic diagram of a test method for a patch of a comparative example. DETAILED DESCRIPTION OF THE INVENTION

[0018] A transdermal electroconductive patch according to one embodiment of the present invention will be described in detail below with reference to the drawings. In the description, the same elements or elements having the same functions may be designated by the same reference numerals, and redundant description will be omitted.

[0019] FIG. 1 is an exploded perspective view of a transdermal current patch according to one embodiment of the present invention. The transdermal current patch 1 is a current patch that utilizes an enzyme-based biobattery, and as shown in FIG. 1, is configured to include an electrode assembly 10 (multiple electrodes), two conductive sections 20 (conductive layer, multiple conductive sections), an adhesive layer 30, a separator 40, and a surface film 50. When in use, the separator 40 is removed from the transdermal current patch 1, and the patch is attached to the skin (living body) of a part of the subject's (user's) body (e.g., shoulder, arm, chin) using the adhesive layer 30. As will be described in detail later, by attaching the patch in this manner, each electrode of the electrode assembly 10 of the transdermal current patch 1 contacts a part of the subject's body via the conductive sections 20, forming an electric circuit that passes a weak current. In this embodiment, the weak current that this electric circuit passes to the part of the subject and its adjacent area is, for example, 0.5 μA / cm. 2 More than 500μA / cm 2 The current density of the transdermal current patch 1 is 500 μA / cm, which is the standard for subjects to feel stimulation. 2 The current density of the transdermal current applied to the subject's area is set to 1 μA / cm. 2 It may be more than that.

[0020] The electrode body 10 has an anode electrode 11 (negative electrode), a cathode electrode 12 (positive electrode), and a lead 13 (connection portion). The lead 13 connects the anode electrode 11 and the cathode electrode 12. The anode electrode 11, the lead 13, and the cathode electrode 12 may be arranged in this order and formed as an integrated member. The electrode body 10 has a thickness of, for example, about 0.1 mm to 2.0 mm. The transdermal current patch 1 preferably has a width of, for example, 1 cm to 10 cm and a length of, for example, 1 cm to 10 cm. The size (area) of the electrode body 10 within the transdermal current patch 1 is smaller than the overall size of the transdermal current patch 1, and the size (area) of the anode electrode 11 and the cathode electrode 12 may be appropriately changed in terms of geometric surface area depending on the area to which they are attached and the range in which a weak current is desired to flow, and may be, for example, 80 cm. 2 Less than or equal to 50cm 2Less than or equal to 40cm 2 Less than or equal to 30cm 2 Less than or equal to 20cm 2 Less than or equal to 10cm 2 Less than or equal to 1 cm 2 Less than or equal to 0.5cm 2 Less than 0.1cm 2 The following can be used. One such small transdermal electrophoretic patch 1 may be applied to the painful area, or multiple transdermal electrophoretic patches 1 may be applied to the painful area. The transdermal electrophoretic patch 1 may be configured to have one electrode body 10 disposed therein, or two or more electrode bodies 10 disposed therein. The shape of the transdermal electrophoretic patch 1 may be any shape, such as a polygon, pentagon, square, triangle, or circle.

[0021] Examples of materials for the anode electrode 11, the cathode electrode 12, and the lead 13 include carbon materials such as carbon nanotubes, Ketjen Black (registered trademark), Glassy Carbon (registered trademark), graphene, fullerene, carbon fiber, carbon fabric, and carbon aerogel; conductive polymers such as polyaniline, polyacetylene, polypyrrole, poly(p-phenylene vinylene), polythiophene, and poly(p-phenylene sulfide); semiconductors such as silicone, germanium, indium tin oxide (ITO), titanium oxide, copper oxide, and silver oxide; and metals such as gold, platinum, titanium, aluminum, tungsten, copper, silver, zinc, magnesium, iron, and palladium. In particular, from the viewpoints of flexibility and electrochemical stability, carbon materials such as carbon fabric and carbon nanotubes are preferred as the material for the electrode body 10. In particular, when immobilizing enzymes on the electrode at a high density, carbon fabric modified with carbon nanotubes is preferred as the material for the electrode body 10.

[0022] A catalyst that catalyzes the oxidation reaction may be supported on the anode electrode 11. Examples of such catalysts include oxidoreductases such as glucose oxidase, glucose dehydrogenase (GDH), fructose dehydrogenase (D-fructose dehydrogenase (FDH), alcohol oxidase, alcohol dehydrogenase, lactate oxidase, and lactate dehydrogenase. In addition to enzymes, an electrode made of one or more of magnesium and a magnesium-containing alloy, aluminum and an aluminum-containing alloy, calcium, iron, zinc, and the like may also be used.

[0023] 2, an electron transfer mediator 15 is immobilized on the anode electrode 11, which promotes electron transfer between the electrode (anode electrode 11) in the biobattery and an enzyme 14 that functions as a catalyst. The anode electrode 11 can efficiently extract electrons from, for example, glucose, which is a fuel, by the enzyme 14 and electron transfer mediator 15 immobilized on the electrode. Various electron transfer mediators 15 can be used here, including, for example, phenazines, viologens, cytochromes (e.g., cytochrome b, cytochrome c), phenoxazines, phenothiazines, ferricyanides such as potassium ferricyanide, ferredoxins, ferrocenes, osmium complexes, and derivatives thereof. Examples of phenazine compounds include, but are not limited to, mediators such as phenazine methosulfate (PMS), methoxy PMS, quinone compounds, and phenylenediamine compounds. Preferred examples of quinone compounds used as mediators include 1,4-naphthoquinone, 1,2-naphthoquinone, and 2-methyl-1,4-naphthoquinone. Phenylenediamine compounds include N-isopropyl-N'-phenyl-p-phenylenediamine (IPPD), N,N'-diphenyl-p-phenylenediamine (DPPD), and N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD). The use of such electron transfer mediators makes it possible to increase the current of the electrical circuit within the aforementioned range when the transdermal electrophoretic patch 1 is attached to a predetermined site on a subject.

[0024] A catalyst that catalyzes the reduction reaction is supported on the cathode electrode 12. Examples of such catalysts include enzymes such as bilirubin oxidase (BOD), laccase, Cu efflux oxidase (Cueo), and ascorbic acid oxidase; transition metal complexes such as iron (II) phthalocyanine; and metal oxides made of platinum, at least one metal selected from the group consisting of titanium, nickel, stainless steel, iron, manganese, zinc, copper, and molybdenum, or at least one metal selected from the group consisting of calcium, iron, manganese, zinc, copper, and molybdenum.

[0025] The conductive part 20 is a water-absorbing body arranged in surface contact with the anode electrode 11 and the cathode electrode 12. The conductive part 20 has a sponge structure containing a dried fuel or electrolyte. The conductive part 20A in contact with the anode electrode 11 contains a fuel such as an organic substance that undergoes an oxidation reaction at the anode electrode 11. Examples of fuels include glucose, fructose, ascorbic acid (vitamin C), alcohol, and lactic acid (see also FIG. 2).

[0026] The water absorbent constituting the conductive section 20 contains a buffer as an electrolyte. A buffer is an electrolyte that becomes a buffer solution when dissolved in an aqueous solution. Examples of buffers include salts of weak acids and weak bases. The water absorbent constituting the conductive section 20 may contain an electrolyte other than the buffer, such as a salt of a strong acid and a strong base, or may not contain such an electrolyte. Examples of electrolytes that constitute the buffer include weak acids such as phosphoric acid, acetic acid, citric acid, and tartaric acid; sodium salts and potassium salts of these weak acids; weak bases such as organic amines, and their salts. The buffer may be composed of two or more electrolytes. When a buffer is not contained in the water absorbent constituting the conductive section 20, the buffer may be contained in the water to be absorbed, or in both the water absorbent constituting the conductive section 20 and the water to be absorbed.

[0027] After the transdermal electrophoretic patch 1 is manufactured and before use, the water-absorbing body of the conductive part 20 is in a dry state. When the transdermal electrophoretic patch 1 is used, water is supplied to the transdermal electrophoretic patch 1, causing the water-absorbing body to absorb water and entrap an electrolyte solution containing electrolytes inside the water-absorbing body. This establishes an electrical connection between the anode electrode 11 and the cathode electrode 12 and the skin through the electrolyte, forming an ion migration path that includes the anode electrode 11, the conductive part 20A, the skin, the conductive part 20B, and the cathode electrode 12. For example, cations such as hydrogen ions and sodium ions are transported from the anode electrode 11 to the cathode electrode 12.

[0028] In the water absorbent body of the conductive part 20, the buffer is encapsulated in a sponge having air bubbles. Examples of sponge materials include synthetic resins such as polyurethane and polyvinyl alcohol; natural polymers such as cellulose; and their derivatives. Fine, open air bubbles are formed inside the sponge. Therefore, by absorbing an electrolyte solution consisting of an aqueous electrolyte solution into the sponge and then drying it, the solute electrolyte in the sponge becomes dry. It is believed that at least a portion of the electrolyte is exposed in a solid state on the inner wall surfaces of the air bubbles without being incorporated into the sponge material. In addition to the electrolyte, the sponge can contain fuel for a biobattery, drugs that can act on living organisms, other additives, etc.

[0029] The sponge of the conductive part 20 has excellent water absorption properties due to capillary action, surface tension, hydrophilicity, etc., and therefore quickly absorbs water simply by immersing a portion of its underside in water. Furthermore, solutes such as electrolytes dissolve in water in the internal space of the sponge's bubbles, preparing an electrolyte solution. Due to the sponge's water absorption ability, the electrolyte solution is mixed uniformly and spreads throughout the absorbent body, connecting the anode electrode 11, cathode electrode 12, and the skin with the electrolyte solution. A sponge-based absorbent body can move water against gravity and even in complex shapes such as three-dimensional shapes.

[0030] The sponge constituting the conductive part 20 may have a pore size of, for example, 10 to 500 μm. Specific examples of pore size include, but are not limited to, 10 μm, 20 μm, 25 μm, 30 μm, 50 μm, 80 μm, 100 μm, 150 μm, 200 μm, 300 μm, and 500 μm, as well as intermediate or nearby values ​​among these. The porosity of the sponge may be, for example, 60 to 95%. Polyurethane sponges are preferred, but sponges with similarly excellent water absorption properties can also be suitably used. For example, Sofras (trade name, manufactured by AION Co., Ltd.) can be used as the sponge constituting the conductive part 20. The thickness of the sponge constituting the conductive part 20 is approximately 0.5 mm to 2 mm, but due to the large number of pores, the thickness can be adjusted when incorporated into the transdermal electropatch 1.

[0031] The transdermal energizing patch 1 that uses a biobattery can use one or more types of enzyme electrodes for the anode electrode 11 or cathode electrode 12. When the water-absorbing body of the conductive part 20 absorbs water, electricity is started to flow to the biobattery, and the transdermal energizing patch 1 is driven by the biobattery. The water-absorbing body of the conductive part 20 retains the electrolyte like a tank, and enables the transfer of substances such as ions and fuel between the anode electrode 11 and cathode electrode 12 and the skin.

[0032] The adhesive layer 30 is a member for attaching the transdermal electroconductive patch 1 to the skin of a subject. The adhesive layer 30 can be formed, for example, from an insulating double-sided adhesive tape. Two openings 31 and 32 are provided in the adhesive layer 30. The anode electrode 11 is housed in one opening 31, and the cathode electrode 12 is housed in the other opening 32. The lead 13 between the anode electrode 11 and the cathode electrode 12 is attached to the portion 33 between the openings 31 and 32. This fixes the position of the electrode body 10 relative to the adhesive layer 30. Furthermore, in the adhesive layer 30, the anode electrode 11 housed in the opening 31 contacts the conductive portion 20A, and the cathode electrode 12 housed in the opening 32 contacts the conductive portion 20B. At this time, the outer frame portions of the conductive portions 20A and 20B are also fixed to the adhesive layer 30. This configuration provides ionic insulation between the conductive portion 20 A and the conductive portion 20 B. The adhesive layer 30 has a thickness of, for example, about 0.1 mm to 0.5 mm.

[0033] Separator 40, together with adhesive layer 30, is a member for achieving ionic insulation between conductive portion 20A and conductive portion 20B, and can be formed, for example, from a release paper whose surface is coated with silicone or the like on a film or paper made of polyester, polyethylene terephthalate, or the like. Separator 40 has two openings 41 and 42, and conductive portion 20A is housed in one opening 41, and conductive portion 20B is housed in the other opening 42. Separator 40 has a thickness of, for example, about 0.05 mm to 0.1 mm.

[0034] The surface film 50 is a member that covers and protects the electrode body 10 and the conductive part 20, and can be formed from, for example, a polyvinyl chloride film. When oxygen is used as a catalyst, a window 51 is formed in the surface film 50 at a position corresponding to the cathode electrode 12 in order to supply an enzyme to the cathode electrode 12. To prevent the cathode electrode 12 from being exposed, the window 51 may be made of an oxygen-permeable material such as cotton to protect the cathode electrode 12.

[0035] The transdermal electrophoresis patch 1 having such a configuration can be configured as a small, thin electrophoresis patch, and can be easily attached to a predetermined part of the subject for a long period of time. When the transdermal electrophoresis patch 1 is attached to a predetermined part of the subject after absorbing water, the anode electrode 11 and the cathode electrode 12 come into contact with the living body via the conductive parts 20A, 20B, forming an electrical circuit that passes a weak current to the predetermined part (including adjacent areas). In the transdermal electrophoresis patch 1, the weak current that this electrical circuit passes to the living body is a current density of 10 μA / cm when the resistance is 5 kΩ. 2 The DC current is configured to be equal to or greater than the above.

[0036] Here, we will explain the electrical resistance of a living body to which the transdermal energizing patch 1 is applied. The electrical resistance of a living body can be divided into the resistance of the skin and the resistance inside the human body. Skin resistance changes depending on the wetness of the contact surface, etc. (See Chapter 4 of the Electrical Work Safety and Health Handbook, Japan Marine Electrical Equipment Association). When the skin is dry and hardened, the skin resistance is about 10 kΩ, but when sweating, this drops to one-twelfth of that. Furthermore, since the skin resistance when sweating is about 1 kΩ, the transdermal energizing patch 1 according to this embodiment has a current of 500 μA / cm when connected to a resistance of 1 kΩ. 2 The following direct current configuration is desirable, which reduces the sensation of stimulation felt by the subject:

[0037] Figure 3 shows the current density (μA / cm ) of the current flowing through the electrical circuit formed by the transdermal electro-patch 1. 2 ) and the elapsed time (minutes). This current density is the current density when the electrical circuit of the transdermal electrophoresis patch 1 is connected to a resistance of 10 kΩ. With the transdermal electrophoresis patch 1, the current density is slightly high immediately after the start, but as time passes, it settles into the range of the weak current mentioned above. More specifically, the electrical circuit formed by the transdermal electrophoresis patch 1 has a current density of 10 μA / cm when connected to a resistance of 10 kΩ. 2 More than 100μA / cm 2Preferably, the transdermal electrophoresis patch 1 is configured such that the electric circuit is configured to cause the weak current flowing through the predetermined site to be 10 μA / cm or less after a predetermined time (for example, at the latest 10 minutes) has elapsed since the transdermal electrophoresis patch 1 was brought into contact with the predetermined site of the subject. 2 More than 175μA / cm 2 More specifically, the electrical circuit of the transdermal electro-patch 1 is configured so that the current density of the weak current flowing therethrough is 10 μA / cm 2 or less at the latest 10 minutes after the patch is connected to a 5 kΩ resistor. 2 More than 175μA / cm 2 More preferably, the transdermal energizing patch 1 is configured so that the current density of the weak current flowing through the electrical circuit is 10 μA / cm or less after 5 hours have passed since the transdermal energizing patch 1 was connected to a resistance of 5 kΩ. 2 More than 175μA / cm 2 It is preferable that the transdermal energizing patch 1 of this embodiment is configured to maintain the following: In other words, the transdermal energizing patch 1 of this embodiment can be attached to a predetermined part of a subject for a long period of time, and a weak current within a predetermined range can be continuously supplied.

[0038] FIG. 4 shows an example of the current density of the transdermal energizing patch 1. This is a graph of the current density of one sample of the actually manufactured transdermal energizing patch 1. When this transdermal energizing patch was connected to a resistance of 5 kΩ, the current density of the weak current flowing through a specified area was 10 μA / cm after 10 minutes (600 seconds). 2 ~30μA / cm 2 Even after more than an hour had passed, the weak current flowing through the subject's designated area was within the current density range of 10 μA / cm 2 ~30μA / cm 2 The DC current flowing through the electrical circuit of the transdermal electrophoresis patch can be controlled within the above range by changing and adjusting the type and amount of the catalyst and electron transfer mediator used in the transdermal electrophoresis patch 1. However, this electrical circuit has a current density of 35 μA / cm when connected to a resistance of 5 kΩ. 2The device may be configured to pass a direct current of 60 μA / cm or more when connected to a 5 kΩ resistor. 2 The power supply may be configured to pass a direct current of at least 100 W. [Example]

[0039] Here, the effects of using the transdermal current patch 1, which can supply the DC current in the above-mentioned range to a predetermined part of the subject, on a subject will be described using several experimental examples with reference to Figures 5 to 9. Experimental examples 1 to 4 were the following (1) to (4). (1) Delayed muscle pain was evaluated using the transdermal electrolyzing patch 1 (see Figure 5). (2) Results of evaluation of exercise performance using transdermal electropigment patch 1 (see Figure 6). (3) Results of evaluation of the relief of stiff shoulders using Transdermal Electric Patch 1 (see Figure 7). (4) Results of evaluation of the relief of temporomandibular joint disorders using the transdermal electro-patch 1 (see Figures 8 and 9).

[0040] First, a large number of transdermal energizing patches 1 (first example) were produced for use in Experimental Examples (1) to (4). In producing the first example of the transdermal energizing patch 1, the following materials were prepared.

[0041] Electrode body 10: An electrode body 10 having the configuration shown in FIG. 1 was fabricated (prepared) using carbon fiber (manufactured by Toho Tenax) carrying multi-walled carbon nanotubes (manufactured by Baytube). The carbon nanotubes may be manufactured by Meijo Nano Carbon Co., Ltd., and are not particularly limited. The carbon fiber may be manufactured by Toray Industries, Inc., and are not particularly limited. The thickness of the electrode body 10 was 0.3 mm. The area of ​​the anode electrode 11 and the cathode electrode 12 was 0.8 cm2 each. 2The anode electrode 11 was supported with 4-isopropylaminodiphenylamine and glucose dehydrogenase as catalysts. The cathode electrode 12 was made of carbon fiber supported with multi-walled carbon nanotubes and polytetrafluoroethylene. Iron phthalocyanine (manufactured by Tokyo Chemical Industry Co., Ltd.) was supported as a catalyst. The lead 13 was made of carbon fiber. The anode electrode 11 and the cathode electrode 12 were joined to this lead 13 by thermal adhesion.

[0042] Conductive part 20: 300 μL of 50 mM McIlvaine buffer solution (pH 5) and 200 mM glucose solution were added to a polyurethane sponge (Sofras (trade name), manufactured by AION Co., Ltd.), and the sponge was dried to produce (prepared) the conductive part 20. The thickness of the conductive part 20 was 1 mm.

[0043] Adhesive layer 30: A medical double-sided adhesive tape (manufactured by 3M Japan Co., Ltd.) was used as a double-sided tape for skin to prepare the adhesive layer 30. The thickness of the adhesive layer 30 was 0.16 mm.

[0044] Separator 40: Polyester was used as the material to produce separator 40 having the configuration shown in Fig. 1. However, separator 40 may also be made of one-side polyethylene-coated paper, polypropylene, or the like.

[0045] Surface film 50: A separator 40 having the structure shown in FIG. 1 was produced using a polyvinyl chloride film as the material.

[0046] After preparing the materials described above, the electrode body 10, conductive portion 20, adhesive layer 30, separator 40, and surface film 50 were assembled in the order and arrangement shown in Figure 1 to produce a large number of first example transdermal energizing patches 1. The current density of the electrical circuit of the patch according to the first example was as shown in Table 1 below. The "current density" in Table 1 is the value measured approximately 10 minutes after the addition of the solution containing the substrate, and the value decreased slightly after 60 minutes had passed.

[0047] [Table 1]

[0048] In the first embodiment of the transdermal energizing patch 1, the current density of the weak current that flows when the electrical circuit of the patch is connected to a resistance of 10 kΩ is 10 μA / cm at the latest 10 minutes after adding water to the transdermal energizing patch. 2 ~30μA / cm 2 In other words, even after more than an hour had passed, the weak current flowing through the specified area of ​​the subject was within the range of 10 μA / cm 2 The patch was designed to maintain a current density of 39 μA / cm when connected to a 5 kΩ resistor. 2 , the current density when connected at 1 kΩ is 108 μA / cm 2 It was confirmed that the current density of the first example of the transdermal current-carrying patch 1 used in the test was 500 μA / cm 2 It was confirmed that the level was below this level and there was no risk of skin irritation.

[0049] A second example of the transdermal electroconductive patch 1 was also fabricated. To fabricate the patch according to the second example, the following materials were first prepared. The anode electrode 11 used 1,4-naphthoquinone (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of the 4-isopropylaminodiphenylamine used in the first example. Platinum mesh (manufactured by BAS) was used as the cathode electrode 12, and stainless steel wire was used as the lead 13. The anode electrode 11 and cathode electrode 12 were fixed to the lead 13 with instant adhesive. The rest of the assembly was performed in the same manner as in the first example. Power generation was initiated by adding 100 mM potassium phosphate buffer (pH 7) containing 200 mM glucose to the sponge of the conductive portion 20. The current density of the electrical circuit of the patch according to the second example was shown in Table 2 below. The "current density" in Table 2 is the value approximately 10 minutes after adding the solution containing the substrate, and the value decreased slightly after 60 minutes had passed.

[0050] [Table 2]

[0051] In the second embodiment of the transdermal electrophoretic patch 1, similarly to the first embodiment, the current density of the weak current that flows when the electrical circuit of the patch is connected to a resistance of 10 kΩ is 20 μA / cm at the latest 10 minutes after the substrate is added. 2 ~45μA / cm 2 In other words, even after more than an hour had passed, the weak current flowing through the specified area of ​​the subject was within the range of 20 μA / cm 2 The patch of the second example was designed to maintain a current density of 73 μA / cm when connected to 5 kΩ. 2 , the current density when connected at 1 kΩ is 193 μA / cm 2 It was confirmed that the current density of the second example of the transdermal current-carrying patch 1 used in the test was 500 μA / cm 2 It was confirmed that the level was below this level and there was no risk of skin irritation.

[0052] A third example of the transdermal electrophoretic patch 1 was also fabricated. To fabricate the patch according to the third example, the following materials were first prepared. Both the anode electrode 11 and the cathode electrode 12 were made of carbon fiber carrying multi-walled carbon nanotubes. This carbon fiber was electrically connected to an alkaline button battery (1.5V, LR44, manufactured by Panasonic). The anode electrode 11 and the cathode electrode 12 were connected with a stainless steel wire (corresponding to lead 13). The rest of the assembly was the same as for the first example of the transdermal electrophoretic patch 1. Power generation was initiated by adding 100 mM potassium phosphate buffer (pH 7) to the sponge of the conductive portion 20. The current density of the electrical circuit of the patch according to the third example was shown in Table 3 below. The "current density" in Table 3 was measured approximately 10 minutes after the electrical circuit was connected, and the value slightly decreased after 60 minutes.

[0053] [Table 3]

[0054] In the third embodiment of the transdermal electrophoretic patch 1, similarly to the first embodiment, the current density of the weak current that flows when the electrical circuit of the patch is connected to a resistance of 10 kΩ is 70 μA / cm at the latest 10 minutes after the substrate is added. 2 ~100μA / cm 2 In other words, even after more than an hour had passed, the weak current flowing through the specified area of ​​the subject was within the range of 50 μA / cm 2 The patch of the third example was designed to maintain a current density of 147 μA / cm when connected to 5 kΩ. 2 , the current density when connected at 1 kΩ is 411 μA / cm 2 That is, the current density of the third example of the transdermal energizing patch 1 used in the test was 500 μA / cm 2 It was confirmed that the level was below this level and there was no risk of skin irritation.

[0055] [Experimental Example 1] In Experimental Example 1, the delayed muscle soreness was evaluated using Transdermal Electrical Patch 1 (Example 1). A negative control product, which does not conduct electricity and which does not contain glucose dehydrogenase or iron phthalocyanine, which are involved in the transfer of electrons, was also used in the test. In this test, subjects held a dumbbell (7.5 kg for men, 5 kg for women) with their elbows resting on a pedestal, and lifted the dumbbell and returned it to its starting position in one stroke per 4 seconds, repeating this exercise twice consecutively until they could no longer maintain the pace. Thirteen subjects (6 men, 7 women) participated. After completing the dumbbell exercise, the Transdermal Electrical Patch 1 or the negative control product prepared above was applied to the longus muscle of the biceps brachii of the subjects so that current flowed along the muscle fibers, and the current density was adjusted to 10 μA / cm. 2 ~30μA / cm 2A weak current in the range of 100-150°C was continuously applied to a designated area of ​​the subject. This test was conducted without the subject knowing whether they were wearing Transdermal Electrical Patch 1 or the negative control product. This weak current was applied for 12 hours between the end of exercise and one day, and again for 12 hours between one day and two days. Both 12-hour periods included time spent sleeping. After completing the dumbbell exercise, the subjects again underwent a similar dumbbell test at least two weeks later. The subjects who had worn Transdermal Electrical Patch 1 in the first dumbbell test were similarly tested with the negative control product. Meanwhile, the subjects who had worn the negative control product in the first dumbbell test were similarly tested with Transdermal Electrical Patch 1.

[0056] Two days after completing the dumbbell exercises, each subject was asked to evaluate their delayed onset muscle soreness (a type of muscle pain). The evaluation criteria were the Japanese version of the Talag scale, as follows (24 levels in 0.25 increments between 0 and 6). (See Physical Therapy Science, 22(1), 125-131(2007)). 0: No pain. 1: Discomfort 2: Slightly distinct pain 3: A more pronounced pain 4: Clear pain 5: Severe pain 6: Unbearable pain.

[0057] Figure 5 shows the results of the pain intensity after two days. As shown in Figure 5, it was confirmed that the pain intensity when the transdermal electrolyzed patch 1 (first embodiment, with current) was used and an electrolyzed treatment was performed twice for 12 hours after dumbbell exercise was lower than the pain intensity when the negative control product (without current) was applied and no electrolyzed treatment was performed. The p-value was calculated using the Wilcoxon signed rank test, and it was confirmed that p<0.05. Thus, according to Experimental Example 1 using the patch of the first embodiment, when the current density was 10 μA / cm 2 ~30μA / cm 2It has been confirmed that pain in a specific area can be alleviated by passing a weak current in this range to the specific area.

[0058] [Experimental Example 2] In Experimental Example 2, exercise performance using Transdermal Electrical Patch 1 (First Example) was evaluated. In this test, the subjects performed dumbbell exercise similar to that in Experimental Example 1, and the number of times they pressed the dumbbell for the first time was counted. The number of subjects was 13, the same as in Experimental Example 1. After completing the dumbbell exercise, the subjects were given either the Transdermal Electrical Patch 1 (First Example) or the negative control product on the biceps of the upper arm for 12 hours each on the first and second days (12 hours x 2 times), as in Experimental Example 1. Experimental Example 2 was carried out without the subjects knowing whether they had applied the Transdermal Electrical Patch 1 or the negative control product. When the Transdermal Electrical Patch 1 was applied, the current density was 10 μA / cm 2 ~30μA / cm 2 A weak current in the range of 10μA / cm was continuously applied to the designated area of ​​the subject. On the other hand, when the negative control product was applied, the current density was 10μA / cm. 2 ~30μA / cm 2 This means that the process of passing a weak current in this range was not performed.

[0059] Three days after the first dumbbell exercise, each subject performed the same dumbbell exercise until they could no longer lift their arms, and the number of repetitions for the second dumbbell exercise was counted. The ratio of "number of repetitions for the second dumbbell exercise / number of repetitions for the first dumbbell exercise" was then calculated for each subject as the exercise repetition rate (%). As in Example 1, the same test was conducted again after a gap of at least two weeks without applying load to the biceps. This time, the subjects who had applied the transdermal electric patch 1 in the previous dumbbell test were similarly tested with the negative control patch applied. Meanwhile, the subjects who had applied the negative control patch in the previous dumbbell test were similarly tested with the transdermal electric patch 1 (Example 1). Figure 6 shows the calculated exercise repetition rate, divided into Group 1 (with electric current treatment) and Group 2 (without electric current treatment). As shown in Figure 6, it was confirmed that the first group, which used the transdermal energizing patch 1 (first embodiment) and underwent two energizing treatments for 12 hours after dumbbell exercise, was able to increase the number of times they could lift the dumbbell. The p-value was calculated using the Wilcoxon signed rank test, and it was confirmed that p<0.01. Thus, according to Experimental Example 2, which used the patch of the first embodiment, 2 ~30μA / cm 2 It was confirmed that athletic ability can be improved by continuously applying a weak current in the range of

[0060] Next, the same test as in Experimental Example 2 was carried out using the patch of the second example instead of the patch of the first example. However, the application time was 1 hour on the first day and 4 hours on the second day. The subject was a man in his 40s (1 person). As a result, the percentage of exercise counts (%) when the negative control product was applied was 46%. On the other hand, the percentage of exercise counts (%) when the patch of the second example was applied was 152%. Therefore, when the current density was 20 μA / cm 2 ~45μA / cm 2 It was confirmed that athletic ability can be improved by continuously applying a weak current in the range of

[0061] Next, a test similar to that in Experimental Example 2 was conducted using the patch of the third example instead of the patch of the first example. However, the application time was 4 hours on the first day and 4 hours on the second day. The subject was a man in his 30s (1 person). As a result, the percentage of exercise counts (%) when the negative control product was applied was 88%. On the other hand, the percentage of exercise counts (%) when the patch of the third example was applied was 108%. Therefore, when the current density was 70 μA / cm 2 ~100μA / cm 2 It was confirmed that continuous application of a weak current in the range of 1000 to 15000 improves athletic ability. Furthermore, when the pain was evaluated two days later, the pain when the negative control product was applied was rated as "3," while the pain when the patch of Example 3 was applied was rated as "0." In other words, it was confirmed that applying the above-mentioned current has the effect of reducing pain.

[0062] [Experimental Example 3] Experimental Example 3 evaluated the relief of stiff shoulders using the transdermal electro-patch 1. In this test, the transdermal electro-patch 1 (first example) was applied to the painful area on the shoulder of a first group of subjects (15 subjects) for 12 hours, and the current density was 10 μA / cm 2 ~30μA / cm 2 A weak current in the range of 100-1500 kJ / min was continuously passed through a predetermined area of ​​the subject. The pain relief was then assessed after a set period of time (12 hours, 24 hours, 36 hours, and 60 hours). A negative control patch was applied to the painful area of ​​the shoulder of a second group of subjects (15 subjects), and the pain relief due to natural healing alone over time was assessed. The subjects were blinded to which patch they were wearing. The evaluation criteria were the same as in Experimental Example 1, and the extent to which the pain changed from before application was recorded. Figure 7 shows the test results. As shown in Figure 7, it was confirmed that the first group, which received 12 hours of electrical treatment at the painful area of ​​the shoulder using the transdermal electrical patch 1 (first embodiment), had a greater improvement in pain than the second group, which did not receive electrical treatment.

[0063] As a comparative example, a general magnetic therapy device was used and the change in pain was recorded in the same way. 12 subjects participated in the study. The general magnetic therapy device was attached for three consecutive days. As a result, the change in pain was -1 after 24 hours, -0.9 after 36 hours, and -0.79 after 60 hours from the start of attachment of the magnetic therapy device, indicating a tendency for improvement. However, the transdermal electroconductive patch (Example 1) was found to have a greater pain-reducing effect. Furthermore, the transdermal electroconductive patch (Example 1) was attached for a shorter time than the comparative example, and its pain-reducing effect was greater.

[0064] [Experimental Example 4] In Experimental Example 4, the degree of relief of pain from temporomandibular joint disorder using the transdermal electro-patch 1 (first example) was evaluated. In this test, one subject (female, in her 30s) diagnosed with temporomandibular joint disorder was asked to apply the above-mentioned transdermal electro-patch 1 to the painful area of ​​the temporomandibular joint while sleeping for four days so that an electric current would flow along the muscle fibers of the masseter muscle. The current density was 10 μA / cm 2 ~30μA / cm 2 A weak electric current ranging from 0 to 100 was continuously applied to the designated area of ​​the subject. Then, every morning, subjects were asked to rate the degree of pain improvement using a visual analogue scale (VAS) ranging from 0 (no pain) to 100 (severe pain). The degree of pain improvement was assessed by evaluating tenderness, pain when opening the mouth, pain when chewing, and the degree of interference with daily life. Tenderness indicated muscle pain when 1 kg of pressure was applied to the jaw muscles. Pain when opening the mouth indicated jaw pain when opening the mouth. Pain when chewing indicated jaw pain when chewing food. The degree of interference with daily life was assessed by rating the degree of interference from jaw pain on a scale of 0 (no interference) to 100 (extreme interference).

[0065] Here, we will explain temporomandibular joint disorders (TMJ). TMJ disorders are considered the third leading dental disease, alongside tooth decay and periodontal disease. The number of patients with some type of temporomandibular joint (TMJ) symptom is estimated to be approximately 19 million in Japan. The recommended first-line treatment for TMJ disorders is conservative, reversible, and evidence-based (see Guidelines for the Treatment of Temporomandibular Joint Disorders 2020, Japan Temporomandibular Joint Society). The basic treatment for masticatory muscle pain disorder (Type I), the most common type of TMJ disorder, is based on physical therapy. This includes not only patients with Type I alone, but also those with concurrent temporomandibular joint pain disorder (Type II), temporomandibular joint disc disorder (Type III), and temporomandibular joint osteoarthritis (Type IV). Specific treatments include self-massage of the affected area, application of warm compresses to the affected area, and pain relief through electrical stimulation (transcutaneous electrical stimulation therapy). Transcutaneous electrical stimulation therapy is believed to induce muscle contraction and relaxation, thereby relieving hypertonia. However, there are cases where these physical therapies cannot adequately treat the condition. One systematic review stated that transcutaneous electrical stimulation therapy did not demonstrate sufficient effectiveness (T. List, S. Axelsson, Journal of Oral Rehabilitation (2010)). Therefore, there is a need for more effective physical therapies that can provide pain relief.

[0066] Electrical therapy devices other than transcutaneous electrical stimulation therapy have only been applied to the area below the neck, and their effectiveness in treating temporomandibular joint disorders was unknown. In particular, there have been no reported cases of weak direct current being used for temporomandibular joint disorders, and it was unclear how much current was needed to achieve treatment.

[0067] Figure 8 is a table showing the degree of improvement in temporomandibular joint syndrome in Experimental Example 4. As shown in Figure 8, by applying the transdermal electrolyzing patch 1 to the painful area of ​​the jaw while sleeping for four consecutive days and continuously passing a weak current within the above-mentioned range, it was confirmed that the pain of temporomandibular joint syndrome, which is difficult to cure, can be significantly improved. Dramatic improvement was confirmed especially on the fifth day.

[0068] Another test was conducted on one subject (female, in her 60s) who had been diagnosed with temporomandibular joint disorder in the same manner as above. This subject also had Type I, II, III, and IV temporomandibular joint disorders. She underwent standard physical therapy, including self-massage and transcutaneous electrical stimulation therapy, but was unable to relieve her pain. Similarly, the transdermal electroconductive patch 1 (Example 1) was applied while sleeping. However, it was applied once daily for two weeks. As shown in Figure 9, pain relief was observed from the fifth day of use for tenderness and from the first day of use for pain during opening the mouth. Pain relief continued even after two weeks of use, demonstrating greater effectiveness than existing treatments. The transdermal electroconductive patch 1 used in this test was 2 cm wide and 5 cm long. Because pain may occur over a wider area in some subjects, the patch size should be 1 cm or wider, preferably 3 cm or wider, and more preferably 4 cm or wider. The patch length should be 1 cm or wider, preferably 3 cm or wider, and more preferably 4 cm or wider, 5 cm or wider, or 6 cm or wider. When the area of ​​the electric current patch was examined, it was found that it would take 50cm to apply it to the painful area. 2 Less than 40cm, preferably 2 Less than 30cm, more preferably 2 It was found that it is desirable to have a thickness of 1cm or less. 2 More than 5cm, preferably 2 The above patches are desirable, and multiple small patches can be applied to adjust the area to an appropriate level.

[0069] In the above-mentioned Experimental Examples 1 to 4 (first embodiment), the weak current (current density) supplied to the subject was 10 μA / cm 2 ~30μA / cm 2 On the other hand, the slightly higher weak current (20-45 μA / cm) was found to have an effect of improving exercise performance. 2 ) (Example 2), the effect of recovering cell damage was considered to be higher. Therefore, in the treatment of temporomandibular joint disorders, the patch of Example 2 was used with a current of 20 to 45 A / cm 2 By passing a current with a current density of 10 kΩ (when a 10 kΩ resistor is connected), it is expected that the same or even greater improvement effects as those mentioned above will be achieved.

[0070] Furthermore, the current density of the patch in the example of JP 2016-144634 A was verified. Figure 10 shows the test method used for the verification. The verification results were as follows. The metal batteries in the prior art were of the following three types: 1) Titanium and silver 2) Titanium and copper 3) Titanium and zinc In this verification method, 10 mL of physiological saline (PBS) was soaked into a nonwoven fabric, and two metal electrodes were placed on the nonwoven fabric as shown in Figure 10, and electrically connected to form an electrical circuit. This simulated actual use (attachment to a living body). The current value of each of these electrical circuits was measured. The measurement results are shown in Table 4 below. That is, the current density of the current flowing through the prior art electric patch was 0.5 μA / cm 2 It was smaller than that.

[0071] [Table 4]

[0072] In a verification method in which titanium and zinc electrodes were immersed in physiological saline and electrically connected while stirring, when connected to a resistance of 1000 kΩ, the voltage was 700 mV and 0.7 μA / cm 2 Therefore, when a current of 650 μA is applied as described in the examples of JP 2016-144634 A, the cross-sectional area through which the current passes is 100 cm 2 It was confirmed that this required an electrode area of ​​at least 1000mW, resulting in a very large structure.

[0073] As described above, according to the transdermal electropatch 1 of this embodiment, an electric circuit is formed that passes a weak current to a part of the subject by contacting the anode electrode 11 and the cathode electrode 12 with the part of the subject via the conductive parts 20A and 20B, and the weak current that this electric circuit passes to the living body is 0.5 μA / cm 2 More than 500μA / cm 2According to the findings of the present inventors, as described above, the weak current flowing through the living body is an extremely small current (0.2 μmA / cm 2 (less than 0.5μA / cm 2 It was found that by using a direct current with a current density of 500 μA / cm or more, the improving effect on the target area can be significantly improved. Therefore, this transdermal electropatch 1 can improve the improving effect on the target area. Furthermore, when the current density of the current applied to the living body is 500 μA / cm or more, 2 If the current density exceeds this, the user may feel irritation. Therefore, in this transdermal current patch 1, the current density of the current passed through the body is set to 500 μA / cm 2 The electrical circuit is formed so that the current is less than 100 kJ / s. This allows the transdermal energizing patch 1 to be used for a long period of time (by attaching it to a specific area of ​​the user), further improving the effect on the target area.

[0074] Furthermore, in the transdermal energizing patch 1 according to this embodiment, the electric circuit formed has a current density of 10 μA / cm when connected to a resistance of 5 kΩ. 2 This allows for more reliable improvement of the target area. When connected to a 5 kΩ resistor, this electrical circuit has a current density of 35 μA / cm. 2 The current density may be 60 μA / cm or more. 2 The power supply may be configured to pass a direct current of at least 100 W.

[0075] Furthermore, in the transdermal energizing patch 1 according to this embodiment, when connected to a resistance of 1 kΩ, the current density is 500 μA / cm 2 This prevents the user from feeling any irritation, regardless of the condition of their skin, allowing the transdermal electro-patch to be used for a longer period of time with more certainty, thereby further improving the effect of improving the target area.

[0076] Furthermore, in the transdermal energizing patch 1 according to this embodiment, the electric circuit formed has a current density of 10 μA / cm 2 or less of the weak current flowing at the latest 10 minutes after connection to a 5 kΩ resistor. 2 More than 175μA / cm 2 It is configured as follows: By attaching the transdermal electrolyzing patch 1 to the target area for a long period of time, it is possible to continuously improve the improving effect on the target area.

[0077] Furthermore, in the transdermal electropatch 1 according to this embodiment, the conductive portion 20 is composed of conductive portions 20A and 20B corresponding to the anode electrode 11 and the cathode electrode 12, respectively. Each of the conductive portions 20A and 20B includes a sponge having bubbles and a buffer made of an electrolyte, with the solid buffer being exposed on the inner wall surface of the bubbles. At least one of the anode electrode 11 and the cathode electrode 12 carries an enzyme that catalyzes an oxidation-reduction reaction. Furthermore, an electron transfer mediator 15 is immobilized on the electrode carrying the enzyme (e.g., the anode electrode 11), and the electron transfer mediator 15 is a mediator of a quinone compound or a phenylenediamine compound. This configuration more reliably ensures that the weak current applied to the living body falls within one of the above-mentioned ranges, thereby more reliably improving the improvement effect on the target area.

[0078] In the percutaneous energizing patch 1 according to this embodiment, the area of ​​each of the anode electrode 11 and the cathode electrode 12 is 80 cm 2 In this case, the transdermal energizing patch 1 can be made smaller, making it easier to attach the transdermal energizing patch 1 to the target area of ​​the user for a long period of time. This can further improve the improving effect on the target area.

[0079] The transdermal electropatch 1 according to the present embodiment has been described above, but the present invention is not limited to the above embodiment and various modifications can be applied. For example, in the above embodiment, a biobattery is used as an example, but an electric circuit is formed to pass a weak current to a part of a living subject, and the weak current that this electric circuit passes to the part of the subject is 0.5 μA / cm. 2 Other patch configurations may be used as long as they provide a direct current with the above current density. For example, the patch may be configured using a button battery as shown in the third embodiment described above, or a thin-film battery may be used instead of the button battery. However, a small, thin transdermal patch is preferable for long-term application to a subject's body. [Explanation of symbols]

[0080] 1...transdermal electroconductive patch, 10...electrode body (multiple electrodes), 11...anode electrode (negative electrode), 12...cathode electrode (positive electrode), 13...lead (connection part), 14...enzyme, 15...electron transfer mediator, 20, 20A, 20B...conductive part (conductive layer, multiple conductive parts).

Claims

1. A positive electrode and a negative electrode, A conductive part arranged to be in contact with each of the positive electrode and the negative electrode, A connection part for electrically connecting the positive electrode and the negative electrode, A tape having an opening for accommodating each of the positive electrode and the negative electrode and having insulation, A transcutaneous energization patch comprising: Each of the conductive parts has a sponge and a buffer agent made of an electrolyte, and the buffer agent is encapsulated in the sponge, The connection part is arranged on one side of the tape, The conductive part is arranged on the other side of the tape, In the transcutaneous energization patch, an electric circuit for passing a current through a living body by bringing the positive electrode and the negative electrode into contact with the living body through the conductive part is formed. A transcutaneous energization patch.

2. The transcutaneous energization patch according to Claim 1, wherein at least one of the connection part and the conductive part is fixed to the tape by adhesion.

3. The transcutaneous energization patch according to Claim 2, wherein both the connection part and the conductive part are fixed to the tape by adhesion.

4. The transcutaneous energization patch according to Claim 1, wherein the tape is an adhesive tape.

5. The transcutaneous energization patch according to Claim 4, wherein the connection part is fixed to the one surface of the adhesive tape.

6. The transcutaneous energization patch according to Claim 4, wherein the conductive part is fixed to the other surface of the adhesive tape.

7. At least one of the positive electrode and the negative electrode supports an enzyme that catalyzes a redox reaction. The transcutaneous energization patch according to any one of Claims 1 to 6.

8. An electron transfer mediator is fixed to the electrode supporting the enzyme. The transcutaneous energization patch according to Claim 7.

9. The electron transfer mediator is a mediator of a quinone-based compound or a phenylenediamine-based compound. The transcutaneous energization patch according to Claim 8.

10. The area of each of the positive electrode and the negative electrode is 80 cm ２ or less, The transcutaneous energization patch according to Claim 1.

Images